Cargando…

Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer

PURPOSE: Cancer patients with bone metastases (BMets) are predisposed to skeletal complications. Bone-targeted therapies such as denosumab or intravenous bisphosphonates (IVBs) reduce the risk of these complications. This study characterized patterns of IVB use in these patients in the USA. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagiwara, May, Delea, Thomas E., Cong, Ze, Chung, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843817/ https://www.ncbi.nlm.nih.gov/pubmed/24000042 http://dx.doi.org/10.1007/s00520-013-1951-z

Ejemplares similares

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

Bisphosphonates and bone metastases.
por: Morton, A. R., et al.
Publicado: (1988)

Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer
por: Hess, Gregory, et al.
Publicado: (2012)

Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy
por: Holt, Abby, et al.
Publicado: (2014)

Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases
por: Zhang, Gao, et al.
Publicado: (2021)

Retracted: Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
por: Walls, J., et al.
Publicado: (1994)

Health state utilities for skeletal-related events secondary to bone metastases
por: Matza, Louis S., et al.
Publicado: (2013)

Sickle cell bone disease and response to intravenous bisphosphonates in children
por: Grimbly, C., et al.
Publicado: (2022)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
por: Aapro, Matti, et al.
Publicado: (2010)

Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases
por: Pfannkuchen, Nina, et al.
Publicado: (2017)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
por: Dodwell, D. J., et al.
Publicado: (1990)

Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases
por: Matza, Louis S., et al.
Publicado: (2012)

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
por: Polascik, Thomas J
Publicado: (2009)

ODP124 Sickle Cell Bone Disease and Response to Intravenous Bisphosphonates in Children
por: Todd Alexander, R, et al.
Publicado: (2022)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
por: Richhariya, Akshara, et al.
Publicado: (2012)

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
por: Coleman, R. E., et al.
Publicado: (1988)

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases
por: Park, In Hae, et al.
Publicado: (2009)

Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis
por: Liu, Jing, et al.
Publicado: (2015)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary
por: Moretti, Antimo
Publicado: (2021)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012)

The role of bisphosphonates in breast cancer: Development of bisphosphonates
por: Fleisch, Herbert
Publicado: (2002)

Effects of palliative radiotherapy and bisphosphonate usage on bone turnover marker levels in cancer patients with osteolytic bone metastases
por: Göksel, Fatih, et al.
Publicado: (2021)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?
por: Farach-Carson, Mary C., et al.
Publicado: (2017)

Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
por: WANG, XIN, et al.
Publicado: (2014)

Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding ‘risks and benefits of bisphosphonates’
por: Kyrgidis, A, et al.
Publicado: (2009)

The role of bisphosphonates in breast cancer: Direct effects of bisphosphonates on breast cancer cells
por: Senaratne, Siddhika G, et al.
Publicado: (2002)

The role of bisphosphonates in breast cancer: Actions of bisphosphonates in animal models of breast cancer
por: Padalecki, Susan S, et al.
Publicado: (2002)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain
por: Pockett, RD, et al.
Publicado: (2010)

Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment
por: Lee, Seung-Hun, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment
por: Razaq, Abdul, et al.
Publicado: (2019)

Prostatic Carcinosarcoma with Lung Metastases
por: Furlan, Stefanie R., et al.
Publicado: (2013)

Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020
por: Kim, Ashley, et al.
Publicado: (2022)

Observations on Prostatic Cancer with Metastases in Bone
por: Charteris, Alexander A.
Publicado: (1927)

Cannot write session to /tmp/vufind_sessions/sess_0h9f2afq9o1pvj4qvqh9hq991v